Xarelto Lawsuits

Xarelto Side Effects

For those individuals that suffer from clotting problems, which includes strokes, blood clots, and other clotting events that can lead to heart attacks, their doctors prescribe them anticoagulant drugs.  The most popular anticoagulant, is Coumadin, or Warfarin.  Warfarin has been around since 1956, but since that time has become a generic drug.  As a generic drug, the drug companies, such as the makers of Xarelto and Pradaxa, have been searching for replacements for Warfarin.  Both Pradaxa and Xarelto were marketed as providing the same or slightly better results than Coumadin in preventing strokes and other blood clot related events, but were marketed to the public as easier to use because the weekly or monthly blood tests were not required.  Pradaxa was first approved in October 2012 for use in non-valvular atrial fibrillation.  Xarelto was approved in November 2011.

xarelto-riskThe makers of Pradaxa and Xarelto claimed that their drugs were superior to Coumadin, as there was not the monitoring required as with Warfarin.  However, soon after Pradaxa and Xarelto entered the market, the FDA began to see a signal for serious and fatal bleeding events, primarily in older patients with a median age of 80.  Essentially, the FDA was getting numerous reports from both physicians and patients that Xarelto bleeding events were resulting from taking Xarelto and Pradaxa.  This included Xarelto strokes and Xarelto intestinal bleeding incidents.  These reports included XARELTO bleeding events, including XARELTO strokes and XARELTO intestinal bleeds.

In approximately 2011, the FDA issued a warning regarding the use of Pradaxa and the increased risk of serious and fatal bleeding injuries and bleeding events.  With that, the prescriptions of Pradaxa went down, while XARELTO prescriptions and XARELTO use increased dramatically.  According to the IMS health data, the use of Xarelto has rapidly and continuously increased at the expense of Pradaxa.  XARELTO prescriptions and, unfortunately XARELTO injuries increased as well.  By the fourth quarter of 2013, Xarelto prescriptions accounted for 989,000 prescriptions, almost double that of Pradaxa use.  Unfortunately, it is becoming clear that XARELTO use is not any safer than St. Louis Pradaxa use.

Recently, the manufacturers of Pradaxa entered into a $650,000,000.00 to resolve a little over 4,000 claims brought by individuals filing Pradaxa lawsuits that have been injured by Pradaxa use.  In the same regard, there are numerous individuals that have been injured by XARELTO use and may be able to bring XARELTO lawsuits for XARELTO injuries and XARELTO bleeding events.

The FDA adverse event reporting database has also shown a significant increase in Xarelto side effects and Xarelto adverse events being reported.  In particular, since the first quarter of 2013, Xarelto side effects have overtaken Pradaxa side effects in volume of reported serious adverse events.  Beginning from its release in the third quarter of 2011, where there were less than 100 serious Xarelto side effect and Xarelto adverse event reports, in only a year and a half timeframe, that increased to a little under 750 reported serious Xarelto side effects and Xarelto adverse events.  Likewise, the St. Louis Pradaxa side effects and St. Louis Pradaxa adverse events has decreased since the second quarter of 2012.

The XARELTO attorneys at NGK Law are handling XARELTO lawsuits for those individuals injured by XARELTO bleeding injuries and XARELTO bleeding events.  The XARELTO lawsuit attorneys at NGK Law are disturbed by this trend in increased XARELTO bleeding events, and are seeking to hold the manufacturer of Xarelto accountable for the injuries sustained by those taking Xarelto and suffering from XARELTO bleeding injury events and XARELTO injuries.

Contact NGK Law today for a no-cost case review at 314-241-1919 or by filling out our online case review on this web page.